Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Charles River lays off around 70 staffers in relocation as strategic shift begins
(2d)
VC Sofinnova ropes in €650M for biotech, medtech despite 'volatile' environment
(2d)
Sensei shrinks workforce by 65%, terminates 3 executive roles
(2d)
Merck & Co pays $9.2B for owner of influenza antiviral that Janssen rejected
(2d)
BMS and J&J's blood thinner flunks phase 3, denting big blockbuster hopes
(2d)
Analysts skeptical Applied Tx can get rare disease drug to market as FDA talks drag on
(2d)
Chutes & Ladders—Ovid eyes next chapter with CEO transition
(3d)
European investor Medicxi secures €500M biotech fund
(3d)
Pfizer finalizes Metsera buy after contentious bidding war with Novo Nordisk
(3d)
Century, Candel and MacroGenics call time on certain clinical trials to conserve cash
(3d)
BioPharma Dive
Sofinnova Partners raises another $750M to back biotech, medtech startups
(43m)
To Wall Street, a new bidding war puts Alkermes in a tough spot
(2d)
Bristol Myers, J&J’s new blood thinner fails first big test
(2d)
Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal
(2d)
Merck stakes $9.2B on Cidara and its long-acting flu drug
(2d)
Medicxi closes fifth fund to back ‘asset-centric’ startups
(2d)
Day One snaps up ADC maker Mersana in backloaded buyout deal
(3d)
Korro to cut staff, shift strategy as RNA editing drug misses mark in early testing
(3d)
Novartis, with study success, to seek approval of new kind of malaria drug
(4d)
FDA unveils new regulatory roadmap for bespoke drug therapies
(4d)
Endpoints News
Inside the Metsera bidding war; PD-(L)1xVEGF bispecific race heats up; Pazdur tapped as next CDER head; and more
(1d)
FDA updates Sarepta’s Duchenne gene therapy label, requests postmarketing study
(2d)
Onshoring and data 'fidelity': What FDA wants from generic drug user fee talks
(2d)
CHMP endorses Sanofi diabetes drug, Lilly breast cancer drug
(2d)
Zhejiang Doer Biologics unveils first-in-class tri-agonist for high lipids
(2d)
Bristol Myers, J&J’s next-gen blood thinner fails key trial in another setback for factor XI
(2d)
Pfizer reduces stake in BioNTech; Candel pauses pancreatic cancer program
(2d)
Cartesian to pause work in form of lupus, despite trial success
(2d)
Exclusive: The inside story of Pfizer and Novo's fight for the $10B Metsera deal
(2d)
Lundbeck fires the first shot in a bidding war with Alkermes over sleep biotech Avadel
(2d)
BioSpace
BMS Jettisons Coronary Trial for J&J-Partnered Anticoagulant
(2d)
Bayer Layoffs Continued in Q3 but CEO Says Cuts Should Be ‘Incremental’ Moving Forward
(2d)
Another Bidding War Breaks as Lundbeck Bids for Sleep Biotech Avadel
(2d)
Merck Again Brings Out Big Bucks, Buys Cidara in $9.2B Antiviral Push
(2d)
Gilead Looks to Simplify HIV Treatment By Combining Two Leading Drugs In One Pill
(2d)
Pfizer Reportedly Planning to Divest BioNTech Stake
(2d)
How the FDA Is Accelerating Cell and Gene Therapy’s Next Chapter
(2d)
Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama
(3d)
FDA's Bad Rap: Pazdur Steps Up as Agency Continues To Take on Water
(3d)
Korro Suffers Cacophony of Bad News as Lead Candidate Fails, Novo Pauses RNA Deal
(3d)
STAT News
I spent two hours telling a chatbot about mental health problems. Its responses scared me
(1d)
A close friend grapples with James Watson’s complicated legacy
(1d)
Medicare premiums to jump 10% heading into 2026
(2d)
Pfizer closes $10 billion Metsera deal
(2d)
Judge says he’ll approve opioid settlement with OxyContin maker Purdue and Sackler family
(2d)
Celebrating a new, faster path to gene-editing medicines on demand
(2d)
Advocates decry intersex exceptions in trans health bans
(2d)
Up and down the ladder: The latest comings and goings
(2d)
NIH abruptly places outspoken critic of Trump administration on leave
(2d)
We’re reading about a Merck acquisition, Novo facing shareholder backlash, and more
(2d)
BioPharma Trend
Insilico and Eli Lilly Launch $100M Collaboration for AI-Driven Drug Discovery
(6d)
Insilico Presents Eight Oral Cardiometabolic Drug Candidates Designed With AI
(1w)
Companies Making Automated Drug Discovery a Reality
(2w)
Five Companies Leading the Way in 3D Bioprinting
(2w)
Roche and Manifold Bio's $55M-to-$2B Deal to Develop Next-Gen Brain Shuttles for Neurological Diseases
(2w)
Flatiron Health Launches Six AI Blood Cancer Datasets Covering 505,000 Patients
(3w)
Recursion Unveils Whole-Genome Microglia Map With Roche and Genentech
(3w)
New Foundation Model Reportedly Surpasses AlphaFold 3 in Drug-Protein Binding Prediction
(3w)
Flagship Unveils AI Covalent Chemistry Startup; $50M Commitment and Pfizer Program
(3w)
Iambic Reports Early Clinical Activity of AI-Designed HER2 Inhibitor
(4w)
Drug Channels
The $700 Copay That Changed Everything
(2d)
Medicare Part D 2026: Preferred Networks Vanish as the PDP Market Collapses
(3d)
Drug Channels Outlook 2026: Live Webinar with Adam J. Fein, Ph.D., on PBMs, Part D, DTC Strategies, Drug Policy Trends, and More
(4d)
Hubs, AI, and the New Era of Revenue Protection in Patient Access
(1w)
As Pharma Faces Financial Pressure, Pharmacy Delivers Measurable Impact
(2w)
Cigna’s Rebate-Free Pharmacy Model: Three Realities Behind Its Latest Push to Pop the Gross-to-Net Bubble
(3w)
Drug Channels News Roundup, October 2025: Vertical Integration Woes, AFPs Gone Wild, Part D’s Decline, 340Bloat, and Dr. G’s ACIP Haunting
(3w)
Let’s Be DIRECT: We Have an Access and Affordability Problem to Solve
(3w)
The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers’ Vertical Integration with Physician Practices
(4w)
Informa Connect’s Trade and Channel Strategies
(4w)
European Biotechnology Magazine
Sofinnova Partners surpasses target with €650m fund to back up early-stage biotech
(42m)
Medicxi announces new €500m biotech investment fund
(16h)
Virometix: US$15m for Synthetic Vaccines
(2d)
Antibodies: Cornerstone of ADC precision and efficacy
(3d)
Scripta Therapeutics raises $12m to flip the script on drug discovery
(4d)
AZ’s baxdrostat mets endpoint in resistant hypertension
(5d)
AstraZeneca bolsters obesity portfolio with muscle‑preserving buy
(6d)
From method validation to the life-cycle
(6d)
SciVario®twin: One Controller for All Your Needs
(6d)
Breakthrough study reveals stability key for mRNA
(6d)
Drug Hunter
taletrectinib
(2d)
Will a New Binding Approach Reinvigorate Caspase-1 as a Therapeutic Target for Autoimmune Disorders?
(3d)
nerandomilast (BI 1015550)
(3d)
monepantel (NUZ-001)
(5d)
sepiapterin (PTC 923)
(6d)
CHF6333
(1w)
Reimagining Druggability Using Chemoproteomic Platforms
(1w)
Patenting Strategies for Small Molecule Drugs
(1w)
PAD Inhibitors: Multiple Approaches Have Striven to Make it to Clinical Development
(1w)
AG-270
(2w)
Labiotech.EU
10 gene therapy companies you should know about
(2d)
Meet Fusix Biotech: 2025 BIO-Europe Startup Spotlight champion revolutionizing oncology
(2d)
iGEM Jamboree: leap into the synthetic biology future
(3d)
Biosimilars: a vital remedy for Europe’s healthcare challenges
(3d)
Swiss biotech going strong in 2024: 19 companies to put on your radar
(4d)
New cancer cell discovery sheds light on childhood blood cancer
(4d)
BIO Europe partnering: Australian biotech companies share their experiences
(6d)
Top biotech deals in October 2025
(1w)
Next‑generation UTI diagnostics: delivering results in just 35 minutes
(1w)
Novo Nordisk’s pipeline plan: How the pharma giant is refocusing amid major restructuring
(2w)
Bio IT World
Why Are We Focused on Simulation-based Methods for Predicting Binding Affinity?
(2d)
Why Overlooking Female Biology Still Impairs Drug Development
(4d)
United Genetic, Epigenetic Readouts From The Same DNA Molecule
(5d)
Revolutionizing ADC Manufacturing: How Single-Use Technologies Are Reshaping Biopharma Efficiency and Safety
(1w)
DNA Nanotech Brings Precision Drug Monitoring to At-Home Use
(2w)
PacBio Aims for Sub-$300 Genomes with Reusable SMRT Cells
(2w)
NVIDIA Unveils Quantum-AI Integration and Record-Breaking Blackwell Architecture at GTC 2025
(2w)
SandboxAQ Releases New AI Model, Illumina Launches New Business, Thermo Fisher’s New Analyzer
(3w)
Follow the Money: Potential Best-in-Category Weight Loss Drug Tubulis’ ADC Advancement, Trojan Horse Treatment for Cancer
(3w)
AI Model Turns Health Data Into Disease Forecasts
(3w)
GEN News
StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia
(34m)
Merck to Acquire Cidara for $9.2B, Bolstering Antiviral Pipeline
(22h)
Cervical Cancer May Be Treatable with Intranasal Nanogel Vaccine
(1d)
AI Model Could Boost Liver Transplant Efficiency by Predicting Donor Death Timing
(2d)
AI Meets Genetic Agency at Dyno GATC 2025
(2d)
Optical Genome Mapping Links Chromosomal Changes to Recurrent Pregnancy Loss
(2d)
A Future Beyond Animal Testing: Why ORIVA Matters and How Computational Models Bridge the Gap
(2d)
Magnetically Guided Microrobots Deliver Drugs with Pinpoint Accuracy
(2d)
Genetic Agency on Display at GATC 2025
(3d)
Accelerating Clinical Decisions Through Faster Access to Imaging Data
(3d)
Cure Today
Understanding Stage 2 Vaginal Cancer: Symptoms, Diagnosis, and Treatment
(5h)
Understanding Stage 2 Myeloma with Treatment and Next Steps Explained
(9h)
An Overview of Pancreatic Neuroendocrine Tumors (PNETs)
(1d)
Osteosarcoma Guide: Stages, Treatment, Side Effects and Patient Journey
(1d)
TKIs Take Lead After Immunotherapy in Metastatic Kidney Cancer
(2d)
Higher BMI Linked to Better Survival in Localized Kidney Cancer
(2d)
Kidney Cancer Disparities Persist Among American Indian and Alaskan Native Patients
(2d)
Tribute to My Husband: A Partner Who Shows Up
(2d)
Understanding That Not All Lung Cancer Cases Are Linked to Smoking
(2d)
FDA Fast Tracks FOG-001 After Early Tumor Shrinkage in Desmoid Tumors
(2d)
Contract Pharma
Contracting & Outsourcing 2025: Q&A with John Bender of Woodstock
(2d)
Merck 3Q Results
(2d)
Pfizer 3Q Results
(2d)
Abbvie 3Q Results
(2d)
TandemAI Secures $22M Series A Extension
(2d)
Merck to Acquire Cidara Therapeutics
(2d)
Cytovance Biologics Celebrates 20 Years in Oklahoma City
(3d)
Neurvati Neurosciences Appoints New Chief Commercial Officer
(3d)
Domain Therapeutics Names Jean-Marie Cuillerot as Chief Medical Officer
(3d)
JSR Life Sciences to Transfer Crown Bioscience to Adicon Holdings Ltd.
(3d)
Pharma Times
Eisai shares long-term data on lecanemab at neurology congress
(3d)
Mursla Bio partners with global pharma to advance precision medicine in liver disease
(3d)
Evotec earns milestone payment as FDA clears IND for CELMoD candidate
(4d)
Adocia unveils new long-acting peptide platform for diabetes and obesity
(4d)
Real-world data shows AUSTEDO improves life for patients with tardive dyskinesia
(5d)
MSD’s oral cholesterol drug shows promise in late-stage trial
(5d)
MiNK Therapeutics unveils promising results for agenT-797 in resistant cancers
(6d)
Procysbi approved for NHS Scotland use in rare kidney disorder
(6d)
Heidelberg Pharma sees promising results in multiple myeloma trial
(1w)
Christie NHS Foundation Trust harnesses AI to revolutionise patient care
(1w)
Medcity News
Startup Iambic Raises $100M for Clinical Trials of AI-Discovered Cancer Drugs
(7h)
Late-in-Life Autism Diagnosis: Why Adults Still Face So Many Barriers and How We Can Do Better
(10h)
Food Is Medicine Needs Data To Thrive
(10h)
Merck Makes Big Antiviral Move With $9B Deal to Land Cidara’s Late-Stage Drug for Flu Prevention
(2d)
Bridging the Gap Between Data and Quality Improvement for Hospitals
(2d)
How to Choose the Right Dental Supply Company for Your Practice
(2d)
AI Companies That Invest in Better Data Pipelines are Winning Faster Regulatory Approvals — Here’s Why
(2d)
What Excites Zimmer Biomet’s CIO About MedTech Right Now?
(2d)
Despite Competition, All Big 4 Ambient Company CEOs Believe They Will Succeed
(3d)
Pluto Health, Help.AI Team Up to Advance Surgical Care
(3d)
Chemical & Engineering News
Formula-linked infant botulism outbreak prompts food safety questions
(2d)
Nov. 14 Policy Watch: US government reopens, is absent from COP 30 climate conference
(2d)
Small molecule targets glucose processing to slow tumor growth
(2d)
ACS elects first zone councilors
(2d)
Woolly mammoth RNA extracted and sequenced
(2d)
Topsoe plant promises 30% efficiency boost for green hydrogen
(2d)
Chemical maker Ineos files 10 lawsuits, is hit with 1
(2d)
Crossword: ‘Say aha!’
(2d)
Chemical makers see cause for optimism in financial results
(3d)
Will quantum computing be chemistry’s next AI?
(3d)
The Pharma Letter
The week in pharma: action, reaction and insight – week to November 14
(13h)
November EMA/CHMP batch of novel medicines backed for approval
(1d)
Switzerland seen as a safe haven for the life sciences
(1d)
March Biosciences
(2d)
Modulight Biotherapeutics
(2d)
Blood thinner failure thins BMS shares
(2d)
Series A extension takes TandemAI fundraising beyond $80 million
(2d)
Hair loss pipeline looking thicker as investors plough $270 million into a cure for balding
(2d)
Terumo BCT names new head of cell and gene therapy business
(2d)
Biokin delays Hong Kong debut as biotech sentiment cools
(2d)
Targeted Oncology
The Targeted Pulse: FDA Decisions and Clinical Advancements
(12h)
Long-Term Follow-Up Confirms Benefits of Low-Dose Seminoma Treatment
(1d)
FDA Authorizes EXENT System to Aid Myeloma Diagnosis
(2d)
FDA Accepts NDA for 177Lu-edotreotide in GEP-NETs
(2d)
Beyond Biomarkers: Immunophenotyping Emerging as Key to Precision IRAE Management
(2d)
Rethinking Advanced Prostate Cancer: Surprising Finds from a Landmark Study
(2d)
How Resting Immune Cells Could Be the Key to Fighting Prostate CancerHow Resting Immune Cells Could Be the Key to Fighting Prostate Cancer
(2d)
Outcomes of Indirect Treatment Comparison Study of RELATIVITY-047 and CheckMate 067
(2d)
Reviewing Long-Term CLL Treatment With BTK Inhibitor Zanubrutinib
(3d)
FDA Fast Tracks Anti-CD127 Monoclonal Antibody for Acute Lymphoblastic Leukemia
(3d)
MedWatch
Lars Rebien is the new chairman at Novo Nordisk
(2d)
CFO rejects notion that collapsed takeover has had consequences for Bavarian Nordic
(2d)
Lundbeck to acquire Irish biotech company for up to USD 2.25bn
(2d)
Novo Nordisk and Eli Lilly deny claims of collaboration with telehealth company
(2d)
Coloplast board opens door to bonus feast in new CEO hunt
(2d)
Bavarian Nordic CFO: Travel vaccine market share growing in Germany
(2d)
First financial report after acquisition drama: Bavarian Nordic clarifies expectations
(2d)
Lundbeck gets marketing approval for migraine drug Vyepti in Japan
(2d)
100 days with Doustdar: Sacrificing values in the pursuit of change
(2d)
Mikael Dolsten withdraws his candidacy for Novo Nordisk's board
(2d)
In The Pipeline
Huge Channels or No Channels: You Pick
(2d)
Biochemical Tungsten - Really
(3d)
Reaction Stirring, Part Two
(4d)
TrkB, BDNF, and Depression
(6d)
Making Pills. But Not Making Them Here.
(1w)
Screening Without Tagging
(1w)
Sarepta: Enough, For God's Sake
(2w)
Taking It Back, The Right Way
(2w)
The Nocebo Effect Hangs Around
(2w)
A Rare Silicon Switch
(2w)
Pharmaphorum
Sanofi's type 1 diabetes drug poised for EU rollout
(2d)
Lundbeck makes bid for Avadel, trying to displace Alkermes
(2d)
Kura scores FDA okay for rival to Syndax's leukaemia drug
(2d)
Medicxi raises €500m for fifth biotech fund
(2d)
Medicxi raises €500m for latest biotech fund
(2d)
MSD said to be close to $9bn+ deal for flu biotech Cidara
(2d)
Update: MSD's $9.2bn deal for flu biotech Cidara confirmed
(2d)
NICE backs Roche's non-Hodgkin lymphoma drug Columvi
(3d)
AbbVie exits alliance with Alphabet biotech Calico; report
(3d)
Novartis says novel drug could counter malaria resistance
(3d)
Drug Discovery Weekly
This week in Drug Discovery (10 – 14 November)
(2d)
New platform hopes to solve strategic misalignment in biopharma
(2d)
Positive data announced for treatment-resistant depression drug
(2d)
Leucid Bio establishes proof-of-concept for CAR-T therapy
(2d)
MHRA approves myopia treatment for children in UK
(2d)
ALS treatment could be worth billions, research suggests
(3d)
Whitepaper: See what’s driving the next wave of degrader discovery
(3d)
See what’s driving the next wave of degrader discovery
(3d)
Radiotherapy drug delivers promising early tumour treatment
(3d)
Covid-19 mRNA vaccine boosts cancer response, study shows
(3d)
HIT Consultant
How Visitor Management Can Make or Break Safety Plans
(2d)
“How to Make Wound Recovery and the Healing Process More Accessible in America”
(2d)
Carrot Partners with ŌURA and Dexcom to Power Metabolic-Fertility Health with Biometric Data
(2d)
Cityblock Health and Mercy Health Partner to Transform Medicaid Care in Ohio
(2d)
CHIME-KLAS: The Digital Health Most Wired National Trends Report 2025
(3d)
Life or Death Logistics: Why 1 in 5 Donated Organs Are Not Transplanted Due to Communication Failure
(3d)
Fundamental XR and Elsevier Launch Mixed Reality Innovation Program for Enterprise AI
(3d)
AISAP Launches FDA-Cleared Platform in Ghana to Solve Cardiologist Shortage
(3d)
How AI Frees Nurses and Clinicians to Focus on Care and Quality
(3d)
AI Risk Alert: Hospitals Underinvest in Governance Despite Looming 2026 Scrutiny
(3d)
Insights: Pink Sheet
Sarepta’s Elevidys Limited To Ambulatory DMD Patients; Study In Non-Ambulatory Patients Planned
(2d)
Adverse Events: Professional Education, Electronic Records Integration Would Improve Report Quality
(2d)
CNPV II: Secondary Indications Feature In Second Batch Of US FDA Voucher Winners
(2d)
Wiskott-Aldrich Syndrome Gene Therapy Among 10 New Drugs To Win EMA OK
(2d)
EMA Backs Sanofi’s Teizeild For Type 1 Diabetes, Company Holds Fire On Extended Indication In EU
(2d)
UK MHRA Closes RegulatoryConnect Portal Less Than Two Years Post-Launch
(2d)
Is US FDA Biosimilars Office Next In Line For Promotion?
(3d)
Beyond The Hype: AI Use Cases In Drug Development
(3d)
What US FDA’s Pazdur’s Long Oncology Track Record Portends For CDER
(3d)
Brazil Bets On AI To Cut Backlog Of Regulatory Applications
(3d)
BioXconomy
Supporting the growth of clinical trials in Africa
(2d)
Africa’s clinical trial expansion hindered by logistics challenges despite growing population
(2d)
Clinical trial design and operations in genome editing therapeutics
(2d)
BIO-Europe
(2d)
HOTH Therapeutics Presents Early Stage Oncology, Dermatology and Neurology Pipeline
(2d)
Medicxi closes $581m Fund V to accelerate asset-centric biotech investments
(2d)
Immuneering: Atebimetinib MEK Inhibitor for Pancreatic Cancer
(3d)
Industry leaders advocate for balanced IRT sponsor-vendor relationships
(3d)
Women's health investment surges, but systemic barriers remain
(3d)
Tiny peptide CAQK triggers damage repair following traumatic brain injury
(4d)
BioCentury
EMA’s CHMP recommends five new products
(2d)
Catalyst-driven week in venture and public equity: Finance Report
(2d)
FDA’s label changes to Sarepta’s Elevidys address physician concerns
(2d)
‘Sharp focus’ on well-positioned assets to drive Medicxi’s €500M Fund V
(2d)
Pharma’s commercial revolution: How integrated DTC models elevate and empower patients
(2d)
Cidara’s Cinderella year ends with $9.2B Merck takeout bid
(2d)
America welcomed Elias Zerhouni — today the door would be closed
(2d)
MFN scheme is less onerous than expected
(2d)
SITC features bispecific solutions for solid tumors
(3d)
Beijing’s Jacobio unveils two CEO structure, and more C-suite moves
(3d)